Background -The effects of P2 adrenergic
agonist, increases the ventilatory responses to hypercapnia (HCVR) and hypoxia (HVR) in normal subjects. Methods -HCVR was tested with a rebreathing method and HVR was examined with a progressive isocapnic hypoxic method in 11 normal subjects. Both HCVR and HVR were assessed by the slope of occlusion pressure (P0.1) or ventilation (VE) plotted against end tidal carbon dioxide pressure and arterial oxygen saturation, respectively. Respiratory muscle strength, spirometric values and lung volume were measured. After a single oral administration of 5mg fenoterol or placebo HCVR and HVR were evaluated. Results -Fenoterol treatment did not change the specific airway conductance or forced expiratory volume in one second. Respiratory muscle strength did not change. Fenoterol increased the slope of the HCVR of both Po., (from 0-251 (0.116) to 0-386 (0.206) kPalkPa, average increase 71%) and VE (from 10-7 (3.4) to 15-1 (4-2) l/min/kPa, average increase 52%), and shifted the response curves to higher values. For the HVR fenoterol increased the slopes of both Po., and VE (from - [4] [5] [6] (2.00) x 10-3 to -7*99 (4.29) x 10-' kPa/ %, an average increase of 83%, and from -0-221 (0.070) to -0-313 (0.112) IIminP/o, a 44 5% increase, respectively), and shifted the response curves to higher values. Conclusion -Acute administration of fenoterol increases the ventilatory responses to both hypercapnia and hypoxia in normal subjects. P1., and Sao2 (AVE/ASao2 and AP0.,/ASao2, respectively).
RESPIRATORY MUSCLE STRENGTH
As we had previously found that fenoterol increased the strength of the fatigued canine diaphragm,'3 respiratory muscle strength was assessed by measuring mouth pressures during maximal static inspiratory (PImax) and expiratory (PEmax) efforts against a closed valve with a small air leak to prevent glottic closure. '4 Pimax was measured at FRC and residual volume (RV) and PEmax was measured at FRC and total lung capacity (TLC) with a differential pressure transducer (Validyne MP -45 + 250 mm Hg). The determinations of Pimax and PEmax were repeated until three measurements varying by <5% and sustained for >2 seconds were recorded; the highest value thus obtained was reported.
PROTOCOL
The study was performed at the same time of day on two different days at least two days apart and within a seven day interval. Subjects were instructed to refrain from caffeine-containing beverages, alcohol, and other drugs for 24 hours before the study. HCVR was examined in all subjects while HVR was measured in seven of the 11 subjects. On each test day the baseline measurements of pulse rate (PR), blood pressure (BP), ventilation and PETCO2 were performed at rest. Either 5 mg fenoterol (Boehringer Ingelheim of Japan, Kawanishi, Japan) or placebo was then administered orally in a randomised, double blind, crossover design on the first or second day. Two hours after fenoterol or placebo administration, pulmonary function tests, respiratory muscle strength, heart rate, blood pressure, ventilation, and PETCO2 were measured and HCVR and HVR were then calculated. For HVR PETCO2 was controlled at the baseline level before administration of fenoterol or placebo because fenoterol could decrease PETCO2. The 1 and 2 ). VE at PETCO2 of 60 mm Hg (-8 kPa) was 39-6 (12-6) 1/min with fenoterol, which was higher than the value with placebo (31-2 (7-6) 1/min) (p<001). P0., at PETCO2 of 8 kPa (0 70 (0 35) kPa) after fenoterol was higher than after placebo (0-54 (0-21) kPa) (p<0 05). Fenoterol increased the slopes of VE and Po., in HVR. The activity of the carotid body chemoreceptors increases with decreasing Pao2.'9 Isoprenaline is known to stimulate the carotid body through a i adrenergic mechanism.'`356 Fenoterol is a selective P2 adrenergic agonist but also has weak , activity. 20 In the present study fenoterol did not affect the resting level of PETCO2 so that the level of carbon dioxide did not affect HVR. It is therefore possible that fenoterol augmented the response of the carotid body in hypoxia, probably through , activity. The heart rate increased by 8% after fenoterol, which is also known to increase cardiac output,2' and this in turn may increase ventilation. 22 Fenoterol increased HCVR as measured by PO., and VE. Response to carbon dioxide inhalation is thought to occur through the stimulation of the medullary chemoreceptors in hyperoxia. Carbon dioxide also stimulates the peripheral chemoreceptors, but their contribution to overall stimulation by carbon dioxide is thought to be small in the presence of hyperoxia. 23 It is possible that fenoterol stimulates the central chemoreceptors, thereby increasing HCVR. adrenergic agonist actions are accompanied by an increase in metabolic activity.24 Although we did not measure oxygen consumption in our study, fenoterol increased resting VE without any changes in PETCO2 and Po.1 suggesting that it raises the metabolic activity thus increasing resting VE. It is known that the increased metabolic rate, which is associated with hyperthyroidism, exercise, or feeding, may stimulate peripheral and/or central chemoreceptors.25 27 In conclusion, fenoterol stimulates ventilatory chemosensitivity although it is unknown whether the mechanisms are the direct 0i receptor mediated effects on peripheral and/or central chemoreceptors, or the indirect effects on factors such as metabolic rate. Fenoterol is a potent bronchodilator and may be beneficial in patients with chronic obstructive pulmonary disease who have a tendency toward hypercapnia. However, further clinical studies are needed.
